Didn't think you were pumping at all. So you are basing your statement on the slide that says "initiate late stage FDA registration trials Q1." ?
I'm a bit confused here because I e-mailed Michael Lee and he told me phase III data for Indaflex was not likely until early 2009.
I've done my research and it seems to me Q3/Q4 2008 could be big for alrx with Vansolin entering clinical trials.
One unknown here is the formulations alrx made for the large cap pharma. If they decide to pursue one or more, that would be great news.
I think there is great potential here. Revenues will start coming in from China in 2009 and if revenues from Indaflex in Mexico keep increasing, that could become a nice source of income. Vansolin looks very promising and I also like the iNOS inhibitors, although they are only preclinical right now.
1 member recommends this.
